Nivolumab is a fully human IgG4 PD1 immune checkpoint inhibitor that selectively blocks PD1 expressed in T cells and PD-L1 and PD-L2 expressed in tumor cells and other immune cells (32). This evidence concerns the gene PDCD1 and neoplasm.